Vivo Capital, LLC Terns Pharmaceuticals, Inc. Call Options Transaction History
Vivo Capital, LLC
- $472 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TERN
# of Institutions
134Shares Held
84.3MCall Options Held
173KPut Options Held
89.5K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$53.3 Million2.36% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$49.4 Million1.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$48.9 Million0.99% of portfolio
-
Morgan Stanley New York, NY7.25MShares$47.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.31MShares$28.1 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $246M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...